TORONTO, Aug. 19 /CNW/ - Amorfix Life Sciences, a company focused on treatments and diagnostics for brain wasting diseases, announced today that it will set up the EP-vCJD(TM) assay system in the Prion Laboratory at the British National Institute for Biological Standards and Controls (NIBSC) outside London and begin to test fresh human blood samples as part of the ongoing assay validation process announced earlier this year. Based on the performance of its EP-vCJD(TM) assay, Amorfix received and accepted an invitation from the British government to further qualify the specificity of the assay using British blood donor samples to be supplied by the National Blood Service.
